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Type II diabetescles (pMP) have been shown to be pro-aggregatory and retain most of their
platelet membrane markers. Recent studies have correlated elevated pMP levels with pathogenesis of
diabetes mellitus and cardiovascular disease. The pro-aggregatory effect of pMP has been largely attri-
buted to their negatively charged outer surface and activation of factor X by membrane associated Tissue
factor (TF). Here we sought to investigate whether, like platelets, protein disulﬁde isomerase (PDI) is
present on the surface of pMP and, if so, to analyze its contribution to platelet hyperaggregability and
insulin degradation. Using a ﬂuorescent assay based upon a novel pseudo-substrate of PDI, ﬂow
cytometry and immunological techniques, we have demonstrated the presence of PDI on the surface of
pMP (termed msPDI) and its ability to inﬂuence insulin-mediated Akt phosphorylation (Thr308) in 3T3-L1
ﬁbroblasts. Moreover, pMP are shown to contain catalytically active PDI, capable of both promoting
platelet aggregation and disrupting insulin signaling. pMP increased initial rates of aggregation by 4-fold
and the pro-aggregatory activity of pMPs could be attenuated with an anti-PDI antibody. The pMP
insulin-reductase activity was further attributed to PDI based on the ability of anti-PDI antibodies to block
the degradation of insulin, thereby restoring insulin signaling. Plasma pMP counts were also obtained
from diabetic (n=10) and non-diabetic individuals (n=10) and found to be elevated in the diabetic state.
Detection of increased levels of PDI-containing microparticles in patients with T2D raises the possibility
that platelet hypersensitivity and insulin desensitization observed in diabetes can partially be attributed
to msPDI activity.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
PDI (protein disulphide-isomerase) is a ubiquitously expressed
enzyme primarily located in the endoplasmic reticulum [1] and
known for its ability to catalyze oxidation, reduction and isomeriza-
tion of disulphide bonds [2]. However, it has been established that PDI
is secreted from a variety of cell types [3] where it can bind to the
exofacial surface [4]. The physiological role of cell-surface PDI (csPDI)
has been implicated in various physiological processes such as cellular
adhesion, viral entry and progression of many diseases [3]. Platelet
surface PDI (psPDI) has been studied extensively for its role in platelet
activation/aggregation [5-7]. Essex and Li [6] have shown that
inhibition of psPDI prevented platelet aggregation and secretion.P, microparticles; FITC, ﬂuor-
isulﬁde; msPDI, microparticle-
ll rights reserved.Later, Lahav et al. [7] showed that integrin-dependent adhesion to
ligands is mediated by psPDI. One of the challenges in studying csPDI
and secreted PDI is the lack of sensitive assays that can detect low
levels of enzyme in crude sample preparations. Here we have used a
highly sensitive ﬂuorescent assay recently developed in our lab [8]
that can detect femto-moles of PDI and therefore is suitable tomonitor
continuous cell-surface PDI activity. This new PDI assay, along with
immunological techniques and ﬂow cytometry, was used to char-
acterize, for the ﬁrst time, platelet-derived, microparticle-surface PDI
(msPDI). Platelet-derivedmicroparticles (pMP) were ﬁrst described by
Wolf in 1967 [9] as platelet dust that were later shown to be formed by
in vivo fracturing of platelet pseudopods [10]. These particles are less
than 1 μm in diameter and are very well known for their pro-
coagulant, thrombogenic and pro-inﬂammatory activity [11]. Recently
it has been observed that pMP have 50-100-fold higher pro-coagulant
activity compared to activated platelets [12]. Interestingly, an
increased level of microparticles has been reported in patients with
type II diabetes (T2D) and was suggested to be related to enhanced
platelet activation [13]. The pro-coagulant activity of pMP has mainly
Fig. 1. Activity and western blot analysis of msPDI: 5 μL of pMP (2.5⁎107/mL) was added
to PDI assay buffer containing 150 nM di-E-GSSG and 2 μM DTT and the activity was
monitored as a function of time (mean±SD, n=5, ⁎pb0.001). In the ﬁgure ‘blank’
represents di-E-GSSG incubated with DTT alone. The increase in ﬂuorescence was
converted to [EGSH] produced by using a standard of plot of [EGSH] versus ﬂuorescence.
Western blot of 20 μL MP shows an anti-PDI reactive band at 58 kDa (n=3).
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Activation of factor X is regulated by tissue factor (TF). Recent studies
have suggested the role of PDI-isomerase as well as chaperone activity
in the regulation of cell-surface tissue factor (TF) pro-coagulant
function [14-16]. Here we have explored the role of microparticle-
surface PDI (msPDI) in platelet activation and aggregation and its
possible implications in T2D. Through our present study, we have
demonstrated 1) the presence of catalytically active PDI on pMPs and
2) implications of msPDI in platelet aggregation and insulin degrada-
tion. The ability of PDI to reductively cleave insulin inter-chain
disulﬁde bonds is widely used as a turbidimetric assay for enzyme
activity [17]. We hypothesized that reductive degradation of insulin by
PDI would abrogate functional insulin signaling. Akt/PKB acts as a
central hub through which insulin affects diverse processes including
glucose uptake [18], glycogen storage [19], protein synthesis [20] and
cell survival [21]. Thus, phosphorylation of Akt/PKB Thr308 was used
as a handle to assess degradation of insulin by microparticle-derived
PDI and the consequent loss of signal transduction.
2. Experimental
2.1. Materials
Human recombinant insulin, Eosin, dithiothreitol (DTT), oxidized
glutathione (GSSG), iodoacetic acid (IAA), sodium orthovanadate
(Na3VO4) and sodium ﬂuoride (NaF) were obtained from Sigma
(Mississauga, ON). Caliculyn A was obtained from LC laboratories
(Woburn, MA). RL90 anti-PDI antibodies were obtained from Abcam
(Boston, MA). Fluorescent beads (0.5 μM diameter) were obtained
from Polysciences, Inc (Warrington, PA). Alexaﬂuor 633 was obtained
from Invitrogen (Carlsbad, CA). Akt and phospho-Akt (Thr308)
antibodies and the appropriate control cell extracts were obtained
fromCell Signaling Technology (Danvers,MA). 3T3-L1 ﬁbroblasts were
obtained from ATCC (Manasass, Va) and cultured at 37 °C in DMEM
containing 10% calf serum under an atmosphere of 5% CO2. Cells were
grown to about 75% conﬂuence in 20 cm culture dishes and then
serum starved for 24 h before experimentation.
2.2. Methods
2.2.1. Preparation of dieosin glutathione disulﬁde (di-E-GSSG)
di-E-GSSG was prepared as described previously [8]. Brieﬂy, GSSG
was incubated with 10-fold molar excess of eosin-isothiocyanate in
phosphate buffer (100 mM sodium phosphate and 2 mM EDTA, pH
8.5) for 8 h at room temperature (25 °C) followed by the separation
through a Sephadex G-25 column (100 mm×10 mm). The samples
were tested for maximum ﬂuorescence on a Varian Cary Eclipse
ﬂuorescence spectrometer with excitation at 525 nm and emission at
545 nm after the addition of 10 mM DTT. All the fractions that showed
70-fold increase in the ﬂuorescence were pooled and stored at -80 °C.
Increase in ﬂuorescence was monitored as a function of [EGSH]
(e=88,000 M-1cm-1) and the standard plot was generated with
excitation at 525 nm and emission at 545 nm. This standard plot was
used wherever quantiﬁcation of the reduction of [di-E-GSSG] to
[EGSH] was required.
2.2.2. Diabetic inclusion criteria healthy versus diabetics
Healthy human subject (n=10), ages 35-70 years were chosen to
participate in the study only if they showed no overt symptoms of
disease and were taking no medication. Diabetic human subjects,
ages 35-70 (n=10) were chosen to fulﬁll the criteria of the Expert
Committee on the Diagnosis and classiﬁcation of Diabetes Mellitus
(Type 2) [22]. Patients on diet treatment alone or diet treatment in
combination with oral hypoglycemic agents were included in the
study, however, subjects taking investigational agents, insulin or
that were pregnant were excluded from the study. The experi-mental protocol was approved by University of Windsor Research
Ethics Board.
2.2.3. Isolation of microparticles
pMP present in plasma were isolated as described by George et al.
[23] with some modiﬁcations. Brieﬂy, 1 U of blood was centrifuged at
1000 g for 20 min at room temperature to separate platelet from
plasma. The supernatant was separated and centrifuged at 5000 g
twice for 15 min. The supernatant from second centrifugation was
then centrifuged at 35,000 g for 45 min and the pellet obtained was
dissolved in 100 μL of PBS and labeled as plasma-MP. Microparticle
count was adjusted to 2.5⁎107/mL for disulﬁde reductase activity
using 0.5 μM latex ﬂuorescent beads and ﬂow cytometry as described
by Bode et al. [24].
2.2.4. Platelet aggregation
Platelets were isolated from whole blood by centrifugation. In
short, whole blood was drawn into 4.5 mL tubes containing buffered
sodium citrate. PRP was separated from the other cellular components
of blood by centrifugation for 30 min at 190 g and then carefully
withdrawn using a plastic Pasteur pipette. Prostaglandin E1 was added
to PRP to a ﬁnal concentration of 1 μM to prevent aggregation and then
spun again for 15 min at 500 g. The platelet pellet was then washed
twice by two successive additions of 5 mL of HEPES-ACD pH 6.2 and
spinning for 15 min at 500 g. The resultant pellet was gently
resuspended in HEPES-ACD buffer and adjusted to a count of 1010
platelets/mL. 108 washed platelets were then suspended in triplicate
in a total volume of 100 μL in the wells of a microplate with varying
microparticle counts. Platelet microparticles were treated for 30 min
with 10 μL/mL RL90 anti-PDI antibodies and the excess of RL90 was
removed by centrifugation at 35,000 g. The pellet was washed once by
suspending the pellet in PBS and centrifuging at 35,000 g. Finally, the
pellet was resuspended in PBS and effect on platelet aggregation
assessed by comparison to the effect of an equal count of untreated
microparticles. Samples were then stimulated with 0.5 U/mL
thrombin at 37 °C and the induced rates of aggregation (measured
as the optical density at 630 nmwith intermittent shaking on a Biotek
Elx808 absorbance microplate reader, Winooski, VT) compared to
unstimulated platelet controls.
2.2.5. Kinetics of PDI-dependent disulphide reduction
PDI disulphide reduction activity of pMP (10 μL to 20 μL of
2.5⁎107) was monitored in PDI assay buffer containing di-E-GSSG as
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in ﬂuorescence was monitored at 545 nm with excitation at 525 nm.
The activity was inhibited using anti-PDI antibody (RL90) (10 μg/mL).
2.2.6. Analysis by ﬂow cytometry
Microparticles were analyzed in a Cytomics FC500 ﬂow cytometer
(Beckman Coulter, USA). Forward (FSC) and side scatter (SSC) were set
at logarithmic gain and triggering were set at FSC. The origin of MPs
from platelet precursor was established by labeling with FITC-CD61
antibody (1:50 dilution). Surface characterization of pMPwas done by
FITC-Annexin V (1:50 dilution) and Alexa-PDI antibody (1:50 dilution)
labeling. FITC-labeled isotype-matched control antibody (IgG1) was
used to set the ﬂuorescence threshold for monoclonal antibodies. For
quantiﬁcation of diabetic and non-diabetic plasma samples, 100 μL of
plasma was directly analyzed for the presence of pMP and the
quantiﬁcation was done as described earlier [24]. Western blot
analysis was performed as described for Akt experiments.Fig. 2. pMP were characterized ﬁrst by FSC/SSC plot before (A and B) and after (C and D)
performed by using FITC-CD-61 (ex. 485, em. 518, y-axis) and Alexa-anti-PDI antibody (x-axis
633 em. 647, y-axis) showed the presence of CD61 and PDI on pMPs (E). Anti-PDI antibody sh
V (F) (mean±SD, n=5).2.2.7. Signaling properties of reductively degraded insulin
PDI is known to possess insulin-reductase activity [17]. To deter-
mine whether insulinwas capable of inducing Akt Thr308 phosphory-
lation after reductive degradation by protein disulﬁde isomerase,
10 μM insulin was incubated for 30 min in the presence of 10 μM DTT
and either 2 μMPDI or 2 μM iodoacetylated PDI inwhich the active-site
thiolswere N95% blocked (as determined by residual reductase activity
in comparison to an equivalent concentration of unblocked PDI).
Similarly, insulin was incubated with 1×108 pMP for 3 h in the
presence of 10 μMDTTand either 10 μL/mL RL90 anti-PDI antibodies or
non-speciﬁc IgG antibodies as control.
Insulin was then added to cells to a ﬁnal concentration of 100 nM
and its ability to induce phosphorylation of Akt was compared to cells
treated with insulin alone. After 30 min incubation, cells were
washed once with ice cold HEPES buffer and then scraped in TRIS-
buffered saline buffer containing 2 mM Na3VO4, 50 mM NaF and
100 nM caliculyn A. Collected cells were then lysed and spun atlabeling with Alexa-labeled anti-PDI antibody (ex. 633, em. 647). Co-labeling (E) was
). Co-labeling experiments with FITC-CD61 (ex. 485, em. 518, x-axis) and Alexa-RL90 (ex
owed positive binding in same subpopulationwhich was positive for CD61 and Annexin
Fig. 3. Thrombin-induced platelet aggregation in the presence of pMP: Platelet
aggregation (109/mL) was studied with (hollow circles) or without (ﬁlled circles)
thrombin. 5 μL (ﬁlled triangles) and 10 μL (ﬁlled squares) of MP (2.5⁎107/mL) were
added to the platelet suspension and the effect on thrombin-induced aggregation was
studied as a function of the maximal observed increase in light transmission. 10 μL of
pMP was also added in parallel after 30 min incubation with anti-PDI antibody (hollow
squares). Plots shown are the mean of samples run in triplicate and representative of
n=3 experiments.
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mixed with loading dye for separation of cellular proteins by SDS-
PAGE. Following separation, proteins were electrophoretically trans-
ferred to PVDF membranes for blotting with anti-pAkt antibodies.
Following 24 h incubation with primary antibodies, membranes were
washed 3× with Tris-buffered saline, then incubated for 1 h with anti-
rabbit HRP-conjugated secondary antibodies, washed and developed
with chemiluminescent peroxidase substrate. Antibodies were then
stripped and reprobed with anti-Akt for imaging of consistent protein
load.
3. Results
3.1. Monitoring microparticle-surface associated reductase activity using
PDI pseudo-substrate, dieosin glutathione disulﬁde (di-E-GSSG)
PDI pseudo-substrate, di-E-GSSG, is a recently introduced ﬂuor-
escent probe for monitoring disulﬁde reductase activity [8]. The
ﬂuorescent moieties of di-E-GSSG are covalently attached to the two
N-terminal residues of GSSG resulting in ﬂuorescence self-quenching
(FSQ) and rendering the molecule relatively non-ﬂuorescent. Upon
addition of reduced PDI, di-E-GSSG disulﬁde bond is cleaved releasing
proximity constraints and enhancing ﬂuorescence by ∼70-fold [8].
Owing to the sensitivity of the assay, we used it here for monitoring
msPDI reductase activity. To this end, pMP were added to the solution
containing, di-E-GSSG and DTT (2 μM). As shown in Fig. 1, while no
signiﬁcant reduction of probe was observed with DTT alone, the
sample containing microparticles showed continuous disulﬁde
reductase activity. More importantly, this activity was blocked to
∼85% by RL90 PDI antibody suggesting that the disulﬁde reductase
activity can be attributed to PDI present on the microparticles surface.
The western blot of MPs showed the presence of a band at ∼58 kDa
(Fig. 1, inset, n=5) that was immunoreactive to anti-PDI antibody, thus
establishing the presence of msPDI in microparticles. ERP-5 is another
member of PDI family that is present on the platelet surface and
involved in platelet activation [25]. To preclude possible cross-
reactivity of anti-PDI antibodies with ERP-5, immunoblots of puriﬁed
ERP-5 with RL-90 and puriﬁed PDI with anti-ERP-5 antibody were
performed. No cross-reactivity with either antibody was observed
(data not shown).
3.2. Flow cytometry analysis of pMP
To further demonstrate the presence of surface-associated PDI in
MPs, plasma isolated MPs were subjected to ﬂow cytometry. The dot-
plot showed the subpopulation of MPs that were identiﬁed by size
distribution (FSC/SSC) as well as by platelet positivity against CD-61,
anti-PDI antibody and FITC-labeled Annexin V [Fig. 2]. Fig. 2(A) and (C)
shows the similar size distribution of microparticles before and after
incubationwithAlexa-RL90 PDI antibody respectively. Fig. 2(B) and (D)
shows the ﬂuorescence of pMP before and after addition of
ﬂuorescently labeled PDI antibody. CD61 (platelet glycoprotein IIIa)
is expressed constitutively by platelets as well as by platelet-derived
microparticles and therefore is one of the markers to ascertain the
platelet origin of MPs in the plasma [12,26]. Co-labeling experiments
with FITC-CD61 (ex. 485, em. 518, x-axis) and Alexa-RL90 (ex 633 em.
647, y-axis) showed the presence of CD61 and PDI in the same
subpopulation of pMP (Fig. 2E). The incubation of pMP with anti-PDI
antibody showed ∼55% positive binding (Fig. 2F) in the same
subpopulation that showed positive binding to Annexin V-FITC and
CD61 conﬁrming the presence of msPDI (n=5).
3.3. Role of msPDI in platelet aggregation
Earlier reports have suggested that pMP enhance the aggregation
of platelets [27,28]. We set out to explore the role of msPDI on plateletaggregation. Addition of 10 μL of microparticles (2.5⁎107/mL) to a
platelet suspension (109 platelets/mL) increased the aggregation
induced by 0.5 U/mL thrombin by ∼4-fold supporting the previous
reports of their pro-aggregatory affects (Fig. 3A). We hypothesized
that this effect could be due to the msPDI that facilitates surface-
surface interaction through disulﬁde isomerization. To test this we
incubated pMP with RL90 anti-PDI antibody for 30 min followed by
two washes to remove unbound antibody. Interestingly, the micro-
particle-mediated potentiation of aggregation was completely inhib-
ited to control levels in the presence of anti-PDI antibody (Fig. 3A,
n=6). These results suggest a potential involvement in platelet
hyperaggregability.
3.4. Reductive degradation of insulin results in the loss of bioactivity
PDI supplied with reducing equivalents is known to reduce the
disulﬁde bonds of insulin resulting in the separation of A and B chains
and the precipitation of insoluble B chain. First we tested whether PDI
positive pMPs are capable of reducing insulin. To this end, insulin was
incubated with pMPs for 1 h in the presence of minimal amount of
DTT (5 μM) as a source of reducing equivalents and then subjected to
non-reducing SDS electrophoresis. The gel was transferred to
nitrocellulose membrane for western blot analysis (Fig. 4 A). While
no signiﬁcant reduction of insulin was observed with DTT alone (lane
1), pMP reduced insulin (2⁎107/mL, lane 3), similar to puriﬁed
recombinant PDI (10 nM, lane 2) in the presence of 5 μM DTT.
Importantly, this effect could be completely reversed by RL90 PDI
antibody (50 μg/mL, lane 4) clearly demonstrating that insulin
reduction is mediated by msPDI.
To our knowledge, there has been little investigation of the
signaling properties of reduced insulin. Therefore, we used recombi-
nant PDI to reduce insulin and compared the ability of reduced and
native insulin to stimulate Akt/PKB phosphorylation in 3T3-L1 cells
(Fig. 4B). Catalytically active, isolated PDI supplied with reducing
agent (DTT) completely abrogated the ability of insulin to induce
phosphorylation of Akt/PKB (Fig. 4B, n=3). Conversely, PDI that was
N95% inactivated by the covalent modiﬁcation of its active-site thiols
exhibited N70% of the ability of control samples (insulin alone) to
induce phosphorylation thus demonstrating the necessity of its
catalytic activity in degrading the bioactivity of insulin. The observed
difference in Akt phosphorylation versus control is likely due to
Fig. 4. (A) msPDI reduces insulin: Insulin (100 nM) was incubated with PDI (10 nM, lane 2), pMP (2⁎107/mL, lane 3), pMP+RL90 (50 μg/mL, lane 4) or pMP+IgG (50 μg/mL, lane 5), in
the presence of DTT (5 μM) for 1 h followed by non-reducing SDS electrophoresis. The gel was transferred to nitrocellulose membrane and subjected to western blot analysis. Lane 1
shows insulinwith 5 μMDTT alone. (B) To assess the ability of PDI to impede insulin signaling, 3T3L1 cells were stimulated with 100 nM human insulin for resultant western blotting
analysis of Akt/PKB Thr308 phosphorylation. Results were compared to basal, unstimulated controls without treatment, phosphorylation induced by insulin treated with 2 μM PDI in
the presence of 100 μMDTT for 30min and insulin treatedwith an identical [DTT] and 2 μMPDI inwhich the active sites were N95% blocked as indicated. Positive controls for both Akt
and pAkt were run in the far left lane. Blot is representative of n=3 trials. (C) The ability of platelet-derived microparticles to degrade insulin and block signaling was subsequently
investigated. Insulin treated as indicated was used to stimulate 3T3L1 cells followed by collection of cell lysate probed for both Thr308 pAkt and Akt. The blot shown is representative
of n=3 experiments above the corresponding bar graphs enumerating the average chemiluminescent intensity measured for pAkt measured by a chemiluminescent imaging. Error
bars were calculated as the standard error of the mean pAkt chemiluminescent intensity.
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clearly demonstrates that enzyme active-site thiols are required for
the insulin-reducing activity and that blockade of these thiols impedes
the loss of functional insulin signaling. Results were then extended to
the insulin-reductase activity of pMP. Insulin when treated with
∼1×108 pMP and 10 μM DTT induced only ∼25% of the phosphoryla-
tion of Akt/PKB versus insulin treated with DTT alone. Notably, the
pretreatment of the pMPs with anti-PDI antibody (RL-90), but not
with non-speciﬁc IgG, restored the signaling capacity of insulin to
N90% of control (Fig. 4B, n=3). Bar graph (below) shows the meanchemiluminescent intensity measured for pAkt in the corresponding
samples of three experiments.
3.5. pMP levels in T2D and control subjects
Elevated levels of pMP have been reported in numerous stress
conditions including T2D [13,29]. Here we compared the relative pMP
as well as msPDI content of plasma from normal (n=10) and T2D
(n=10) subjects. As seen in Fig. 5A, the T2D plasma samples contained
50% more pMPs per 100 μL of plasma. More signiﬁcantly, the pMP-PDI
Fig. 5. (A) The quantiﬁcation of pMP from diabetic and non-diabetic subjects was done
using ﬂow cytometry. For each run, the volume loaded was ﬁxed to 100 μL (⁎pb0.05,
mean±SD n=10). Inset shows the western blot analysis of pMP for the presence of PDI
that is obtained from 10 mL of diabetic or non-diabetic plasma (⁎⁎pb0.05, n=6). (B)
Reductase activity of pMP was estimated by incubating pMP isolated from 10 mL of
plasma with 150 nM di-E-GSSG for 1 h in the presence of 2 μM DTT.
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respectively in T2D. These data suggest that PDI content per
microparticle is relatively constant in T2D and normal subjects and
higher PDI activity observed in T2D is most likely a result of elevated
MP counts.
4. Discussion
In this study we have demonstrated the presence of catalytically
active PDI on platelet-derived microparticles. The PDI activity of pMP
was determined with a ﬂuorogenic PDI pseudo-substrate di-E-GSSG
(Fig. 1). The presence of msPDI was further conﬁrmed by western blot
analysis (Fig.1, inset) aswell as byﬂowcytometry (Fig. 2). Itwas further
shown that microparticles are capable of catalyzing the reduction of
insulin inter-chain disulﬁde bonds in a PDI-dependent manner, thus
interrupting the ability of insulin to induce the phosphorylation of Akt/
PKB in 3T3-L1 cells.
The pro-coagulant activity of pMP has previously been demon-
strated [8]. The bleeding disorder associated with Scott syndrome and
Castaman's disease has been attributed to low levels plasma
microparticles [30,31]. On the contrary, elevated levels of plasma
microparticles are shown to be present where there is thromboem-
bolic risk or vascular damage [32] as well as in cardiovascular diseases
[33] and diabetesmellitus [13,29]. In agreementwith previous studies,we also observed that platelet aggregation increases signiﬁcantly in
the presence of pMP (Fig. 3A). However, this pro-aggregatory effect of
pMP was reversed to control levels in the presence of RL90 antibody
(Fig. 3A), clearly demonstrating the role of PDI in pMP-mediated
stimulation of aggregation.
The pro-coagulant activity of microparticles is generally attributed
to the presence of a negatively charged exofacial surface that binds to
Gla-domains of coagulation factors in the presence of calcium ions and
provides more binding sites per unit surface area as compared to
activated platelets [26]. In addition, it has been shown that pMP have
surface exposed TF, a 45 kDa transmembrane protein that binds to
factor VII and catalyzes the conversion of factor X (inactive) into factor
Xa (active) which, in turn, converts pro-thrombin into thrombin and
hence propagates aggregation. Hogg and coworkers have shown that
the TF is generally in its cryptic formwhere its exofacial Cys186-Cys209
disulﬁde bond is in the reduced state and its activation requires
formation of a disulﬁde bond [15]. This hypothesis was based on the
observation that addition of reducing agent diminished TF activity
while addition of oxidizing agent potentiated it. Our results, together
with this observation, demonstrate the need of studying the co-
localization of PDI and TF on pMP membrane. It is possible that
activation of TF ismediated by the catalytic activity of PDI that converts
the cryptic form of TF into active disulﬁde form. Higher levels of TF
exposing pMP have been reported in uncomplicated T2D [26,34]. This
could be linked to elevated aggregation in diabetic patients through
PDI activity which is likely to be in an oxidized state on account of
elevated oxidative-stress observed in T2D. Therefore, PDI would more
effectively convert reduced-cryptic form of TF into its disulﬁde-active
form on account of its high reduction potential that makes it a better
oxidant for protein thiols. Recently, Furie and coworkers [35] clearly
demonstrated that extracellular PDI is intimately involved in ﬁbrin
generation and thrombus formation in mice. In a parallel but separate
in vivo study, Engelmann and coworkers [36] showed that PDI activates
glutathionylated-cryptic tissue factor through its isomerase activity.
Therefore, on account of the growing evidence of PDI's role in
thrombus formation, it is imperative to study the physiological
consequences of circulatingmsPDI on TFmediated vascular responses.
The results presented here also showed that in terms of sheer
numbers, T2D samples had ∼50% more pMPs than controls (Fig. 5A).
Furthermore, the pMPs fromT2D platelets had∼60%more PDI content
and ∼70% more PDI activity (Fig. 5B). In view of the large contribution
of pMP-PDI to platelet aggregation demonstrated here, elevated
numbers of pMP which result in greater than normal PDI activity
could potentially be a major contributing factor to platelet hyper-
activity observed in T2D. Variable expression of PDI on MP surface in
diseased state, such as in T2D, could be another factor contributing to
the elevated msPDI activity and is a subject of further investigation in
our lab.
Loss of insulin sensitivity and resultant hyperglycemia is a
hallmark of T2D and several explanations to account for desensitiza-
tion have been offered including lipid-induced changes in both insulin
receptor expression [37] and defective insulin receptor substrate
phosphorylation [38]. Evidence for proteolytic mechanisms of insulin
degradation, i.e. insulin-degrading enzyme (IDE) has been reported
[39]. Here we present evidence of microparticle PDI-dependent
reductive inactivation of insulin. Our studies indicate that the
activation of TF and the stimulation of platelet aggregation by the
mechanism proposed require msPDI in the oxidized state while the
disruption of insulin signalingwould require reduced or (1/2-reduced)
PDI. Presumably both of these roles could be fulﬁlled as we expect that
there will be both reduced and oxidized msPDI pools in circulation
and the reduced msPDI pool could be generated by the reduction of
oxidized msPDI by the free thiols on the surface of other cells. The
pathophysiological relevance of msPDI-mediated reductive inactiva-
tion of insulin must therefore await further studies to determine the
redox status of msPDI in normal versus disease states like T2D.
2796 A. Raturi et al. / Biochimica et Biophysica Acta 1778 (2008) 2790–2796Our results show in agreement with previous studies that platelets
of T2D individuals release elevated levels ofmicroparticles.We further
show for the ﬁrst time that microparticles possess catalytically active
surface PDI capable of degrading the bioactivity of insulin. In concert,
these results suggest that msPDI may play an additional role in
degrading functional insulin in T2D.
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